October 2023 - Page 9 of 16

Prostate Cancer Radiation Therapy Research: SBRT vs Surgery; Conventional Radiation vs Large Fraction Radiation

By Peng Geng 2023.10.13

The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of prostate cancer radiation therapy, two phase 3 clinical studies were selected for oral presentation: The PACE-A study explores stereotactic body radiation therapy (SBRT) compared to surgery for localized prostate cancer; The CHHiP study further reports survival and comorbidity outcomes with a 12-year follow-up.

Key Insights from the 2023 ASCO-GU Conference on Sacituzumab Govitecan in Advanced Urothelial Cancer

By Peng Geng 2023.10.13

Advanced urothelial cancer (aUC) has seen remarkable progress in recent years with the emergence of antibody-drug conjugates (ADCs) targeting specific antigens. Trop-2, a cell surface antigen highly expressed in UC, has become a promising therapeutic target. Sacituzumab govitecan (SG), a next-generation Trop-2 ADC, received accelerated approval from the US FDA in April 2021 for treating adult patients with locally advanced or metastatic UC who had prior platinum-based chemotherapy and PD-(L)1 inhibitors. The 2023 ASCO-GU conference unveiled data from various cohorts of the TROPHY-U-01 trial and the latest advancements in UC treatment, encompassing late-line monotherapy, combination therapy, first-line combination therapy, and first-line maintenance therapy. Here, we summarize essential findings from these presentations, anticipating further insights after the conference.

Dr. Kan Gong: Research Progressin ASCO-GU 2023 Kidney Cancer

By Peng Geng 2023.10.13

The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of kidney cancer diagnosis, a novel molecular imaging agent, 89Zr-DFO-girentuximab, has been shown to accurately diagnose clear cell renal cell carcinoma (ccRCC). In the first-line treatment area, the CheckMate 9ER study reported extended follow-up data, while the COSMIC-313 study presented data on IMDC subgroup patients. Additionally, research explored the improvement of complete response rates in first-line immunotherapy patients through local treatments and the benefits of reducing the number and duration of immunotherapy treatments for untreated survival. In the area of second-line treatment, CaboPoint reported positive anti-tumor activity of cabozantinib for immunotherapy-resistant patients.

Dr. Wei Yu: Research Progress in ASCO-GU 2023 Urothelial Carcinoma

By Peng Geng 2023.10.13

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of urothelial carcinoma (UC), significant progress has been made in research. Immunotherapy with immune checkpoint inhibitors (ICIs) in the first-line treatment for advanced UC, as reported in the final analysis of the IMvigor130 study, has provided more information on the population benefiting from immune therapy. Additionally, immunotherapy has expanded into early-stage treatment, with the updated 3-year follow-up data from the CheckMate 274 study showing a Disease-Free Survival (DFS) of up to 52.6 months in the PD-L1 > 1% subgroup. Furthermore, different targets such as Trop-2 and Nectin-4 in antibody-drug conjugates (ADCs) are being explored in various treatment modalities and are extending from later-line to first-line treatment.

Dr. Xinwei Wang: The Molecular Landscape and Clinical Significance of Liver Cancer

By Lynn 2023.10.13

Liver cancer is one of the most prevalent and deadliest cancers in China. Due to the low early diagnosis rate of liver cancer in clinical practice, treatment options such as radical liver resection and transplantation face significant limitations. In recent years, there has been a surge in liver cancer genomics research, providing new insights into early diagnosis, patient stratification, and treatment prognosis. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Conference (APPLE 2023) was held in Seoul, South Korea. During the conference, Dr. Xinwei Wang from the U.S. National Cancer Institute gave a special lecture on "The Molecular Landscape and Clinical Significance of Liver Cancer." Hepatology Digest had the privilege of inviting Dr. Wang to share recent significant developments in this research field and delve into the potential applications and prospects of liver cancer genomics research for early diagnosis and prognosis prediction.

Urinary Tumor DNA for MRD Detection in NMIBC rTURBT

By Peng Geng 2023.10.13

The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off in San Francisco on February 16, 2023. On the second day of the conference, during a special session on urothelial carcinoma, Professor Kyle M. Rose from the H. Lee Moffitt Cancer Center presented a prospective study on using cfDNA/utDNA for MRD detection in NMIBC patients undergoing repeat-transurethral resection of bladder tumor (rTURBT).

Dr Zhu Yao’s Team: Significant Survival Differences in Newly Diagnosed mPC Patients between Asian and Caucasian patients, International Clinical Trial Designs Should Consider This Factor

By Peng Geng 2023.10.13

Are there differences in long-term prognosis between Asian and Caucasian patients with new metastatic prostate cancer (mPC)? A study presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) by Dr. Zhu Yao's team suggests that among patients receiving different treatment regimens, Asian males have superior overall survival (OS) and cancer-specific survival (CSS) compared to white males in this category. This research highlights the importance of considering Asians as an independent prognostic factor when evaluating individual patient outcomes and the need to include an adequate representation of Asian patients in the design of global multicenter clinical trials.

Comprehensive Research from West China Hospital of Sichuan University

By Peng Geng 2023.10.13

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) was held in San Francisco, USA, from February 16th to 18th, 2023. Dr. Qiang Wei and Dr. Hao Zeng's team had multiple findings selected for academic exchange at this ASCO-GU symposium. Their work addressed prostate cancer, urinary tract carcinoma, and kidney cancer, covering prospective clinical trials, retrospective studies, and translational research. They shared and conveyed the "West China Experience" and "West China Plan" on the international stage.

Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

By Peng Geng 2023.10.13

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium for 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. Numerous innovative treatment studies have emerged in the fields of metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and early/localized prostate cancer. These studies encompass a wide range of therapies, including androgen deprivation therapy (ADT), novel hormonal therapy (NHT), PARP inhibitors (PARPi), immunotherapy, nuclear medicine therapy, and localized treatments.

Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor

By Lynn 2023.10.13

The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) recently concluded in Seoul, South Korea, bringing together top experts in liver and biliary system tumors from around the world to discuss clinical hot topics and challenges. Dr. Huichuan Sun from Zhongshan Hospital, Fudan University, China, shares and interprets the latest developments and frontiers, including the Asia-Pacific consensus and groundbreaking research with us.